Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-10-21 | perampanel | Eisai (Japan) | adjunctive treatment of primary generalised tonic-clonic seizures (PGTC) |
Acceptation for review of a sNDA |
2014-10-28 | oprozomib | Onyx Therapeutics (USA - CA) Amgen (USA - CA) | multiple myeloma |
Granting of the orphan status in the US |
2014-10-28 | sodium thiosulfate | Hope Pharmaceuticals (USA - AZ) | dermatomyositis |
Granting of the orphan status in the US |
2018-01-22 | dupilumab | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | moderate-to-severe atopic dermatitis | Granting of a Market Authorisation in Japan |
2015-01-19 | dasabuvir | Abbvie (USA - IL) | chronic hepatitis C |
Granting of a Market Authorisation in the EU |
2017-05-29 | levamisole | ACE Pharmaceuticals (The Netherlands) | nephrotic syndrome | Withdrawal of a market application in the EU |
2016-11-29 | ponatinib | Ariad Pharmaceuticals (USA - MA) |
|
Granting of a Market Authorisation in the US |
2014-11-25 | Cellectis (France) | Granting of a patent | ||
2014-11-24 | Covidien (Ireland) | percutaneous transluminal angioplasty |
Granting of a Market Authorisation in the US | |
2014-11-05 | ramucirumab in combination with paclitaxel | Eli Lilly (USA - IN) | advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma |
Granting of a Market Authorisation in the US |
2016-03-03 | trabectedin | PharmaMar (Spain) Janssen R&D, a J&J company (USA - NJ) Taiho Pharmaceutical (Japan) | advanced soft tissue sarcoma including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline
|
Granting of a Market Authorisation in the US |
2014-11-25 | Sophia Genetics (Switzerland) | breast cancer |
Product launch | |
2014-11-24 | aclidinium bromide/formoterol fumarate 340/12 mcg | AstraZeneca (UK) | chronic obstructive pulmonary disease |
Granting of a Market Authorisation in the EU |
2015-11-24 | sacubitril/valsartan | Novartis (Switzerland) | chronic heart failure with reduced ejection fraction (HFrEF) | Granting of a Market Authorisation in the EU |
2014-12-16 | exisulind | Firc Institute of Molecular Oncology (IFOM) (Italy) | familial cerebral cavernous malformations |
Granting of the orphan status in the EU |
2014-12-16 | single-chain urokinase plasminogen activator | Coté Orphan Consulting UK Limited (UK) Lung Therapeutics (USA - TX) | pleural empyema |
Granting of the orphan status in the EU |
2014-11-13 | ((E)-1-(4\'-chlorophenyl)-3-(4-hydroxy-3-metoxyphenyl)prop-2-en-1-one) | Centre National de la Recherche Scientifique (CNRS) (France) | WHIM syndrome |
Granting of the orphan status in the EU |
2014-12-16 | (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine | Mimetech (Italy) | neurotrophic keratitis | Granting of the orphan status in the EU |
2014-12-02 | rifapentine and isoniazid | Sanofi (France) | latent tuberculosis infection (LTBI) in patients two years of age and older at high risk of progression to tuberculosis (TB) disease |
Granting of a Market Authorisation in the US |
2014-12-16 | 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | AstraZeneca (UK) | multiple system atrophy
|
Granting of the orphan status in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+